DexCom forecasts 15% revenue surge in 2025 as it expands type 2 diabetes reach

Key Highlights from DexCom's Q3 2025 Earnings Call

DexCom, Inc. (DXCM) delivered a strong performance in the third quarter of 2025, with organic revenue growth of 20% compared to the same period in 2024. The company's Interim CEO, Jacob Leach, emphasized the continued success of both U.S. and international operations, highlighting significant progress in the type 2 diabetes market. He noted that coverage for type 2 patients has been established through the national formularies of three of the largest commercial PBMs, with active coverage now reaching nearly 6 million non-insulin lives.

Leach also announced the upcoming release of the DexCom Smart Basal feature, which will be integrated into the DexCom app to simplify and personalize basal insulin titration for users. Additionally, the over-the-counter biosensor, Stelo, exceeded $100 million in revenue within its first year, marking a significant milestone for the company. The G7 15-day system is now fully contracted with Medicare, major commercial payers, and DME partners, signaling a broad rollout strategy.

Customer experience remained a focus, with Leach stating that complaint rates for G7 have remained stable over the past few years, particularly in areas like sensor performance. This indicates that the company is maintaining quality despite scaling up production.

Financial Performance and Outlook

The CFO, Jereme Sylvain, reported worldwide revenue of $1.21 billion for Q3 2025, representing a 22% increase on a reported basis and 20% on an organic basis. U.S. revenue reached $852 million, up 21%, while international revenue grew by 22% to $357.4 million. Gross profit for the quarter was $741.3 million, or 61.3% of revenue, down slightly from 63.0% in the same period last year. Net income was $242.5 million, or $0.61 per share, marking the highest quarterly earnings per share in the company’s history.

Looking ahead, the company raised its full-year revenue guidance to a range of $4.630 billion to $4.650 billion, reflecting a 15% growth for the year. However, gross margin guidance for 2025 was lowered to approximately 61% due to increased scrap dynamics. Operating margin and adjusted EBITDA margin are expected to fall within ranges of 20% to 21% and 29% to 30%, respectively.

Management explained that the base case for 2026 guidance relies on current coverage without assuming expanded access. However, they remain optimistic about potential opportunities for outperformance, such as expanded access and leveraging their innovation pipeline.

Operational Challenges and Strategic Focus

Despite the positive financial results, management acknowledged several operational challenges. Higher-than-expected scrap rates and manufacturing costs were cited as key issues, though improvements are anticipated in the coming quarters. Product quality and deployment challenges were also addressed, with ongoing efforts to enhance Bluetooth connectivity, adhesives, and deployment mechanics.

Analysts raised concerns about new patient starts, decelerating growth trends, and competitive dynamics, particularly regarding future Medicare coverage and pricing. Management responded with a balanced approach, emphasizing the need to address these concerns while maintaining confidence in long-term growth.

Market Expansion and Innovation

DexCom continues to focus on expanding its presence in the type 2 diabetes market, where it has seen strong growth across all segments. The company is also investing heavily in product innovation, with features like Smart Basal set to launch soon. These developments are expected to further solidify DexCom’s position in the healthcare industry.

Final Thoughts

DexCom’s Q3 2025 results reflect robust revenue growth, expanded market coverage, and a commitment to innovation. While the company faces some near-term operational challenges, its leadership remains confident in the long-term potential of its products and services. With a clear roadmap for growth and a focus on improving patient experience, DexCom is well-positioned to continue its trajectory of success in the evolving healthcare landscape.